PDS Biotechnology Corporation
PDSB
We are a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our Versamune T cell activator and Versamune in combination with our interleukin 12 (IL-12) fused anti-body drug conjugate (ADC), PDS01ADC. In addition, we are developing the Infectimune T cell-activator in infectious diseases.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$32M
▲ +8.3% YoY
Op. Margin
–
ROIC
-164.47%
▼ -23.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$19M
▲ +20.8% YoY
Op. Cash Flow (TTM)
-$19M
▲ +20.8% YoY
Net Debt
-$15M
Net Cash Position
Cash & Equiv.
$15M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with PDSB
Held by ETFs
PDSB is in 1 US ETF. The largest of them, with PDSB's weight in each:
PDS Biotechnology (PDSB) in two numbers
Questions about PDS Biotechnology
Does PDS Biotechnology (PDSB) pay a dividend?
No. PDS Biotechnology (PDSB) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 5 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in PDSB's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing PDSB
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.